Donepezil for vascular cognitive impairment
Tóm tắt
Từ khóa
Tài liệu tham khảo
Anon Efficacy and Tolerability of donepezil in vascular dementia: positive results of a 24-week, multicentre, international, randomized, placebo-controlled clinical trial pre-publication report 2002
Bayer A Pratt RD Kumar D A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004 2004
Black, 2003, Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week multicenter internationl randomized placebo controlled trial, Stroke, 43, 2323, 10.1161/01.STR.0000091396.95360.E1
Doody, 2004, Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits, NeuroBiology of Aging, 25, 469, 10.1016/S0197-4580(04)81550-1
Geldmacher, 2002, Donepezil slows functional deterioration in patients with vascular dementia, European Journal of Neurology, 9, 35
Pratt, 2002, Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia, Journal of the Neurological Sciences, 203-204, 57, 10.1016/S0022-510X(02)00266-6
Pratt RD Perdomo CA The Donepezil 307 VAD Study Group Donepezil improves cognition in patients with vascular dementia results from study 307 a 24 week randomized double blind placebo controlled trial Springfield Conference 2002 The International Symposium on Advances in Alzheimer Therapy, Geneva 2002 233
Pratt RD Perdomo CA The Donepezil 307 and 308 VaD Study Groups Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials The 7th International Geneva Springfield Symposium on Advances in Alzheimer therapy 234
Pratt, 2002, Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits, Annals of the New York Academy of Sciences, 977, 513, 10.1111/j.1749-6632.2002.tb04859.x
Salloway S Pratt R Posner H Kumar D Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits 8th Congress of the European Federation of the Neurological Sciences, Paris, France. September 4-7, 2004. Paris, France, 2004 2004
Salloway, 2002, Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients., European Journal of Neurology, 9, 165
Schindler R Perdomo CA Pratt RD Donepezil provides significant benefits to patients with vascular dementia in their ability to perform everyday activities. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004 2004
Seltzer, 2004, Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities., NeuroBiology of Aging, 25, 470, 10.1016/S0197-4580(04)81551-3
Bayer A Pratt RD Kumar D A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004 2004
Doody, 2004, Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits, NeuroBiology of Aging, 25, 469, 10.1016/S0197-4580(04)81550-1
Farlow, 2003, Efficacy of donepezil in vascular dementia, Neurology, 61, 429
Pratt, 2002, Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia, Journal of the Neurological Sciences, 203-204, 57, 10.1016/S0022-510X(02)00266-6
Pratt RD Perdomo CA The Donepezil 307 and 308 VaD Study Groups Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials Springfield Conference 2002, The International Symposium on Advances in Alzheimer Therapy, Geneva 234
Pratt, 2002, Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits, Annals of the New York Academy of Sciences, 977, 513, 10.1111/j.1749-6632.2002.tb04859.x
Salloway S Pratt R Posner H Kumar D Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits 8th Congress of the European Federation of the Neurological Sciences, Paris, France. September 4-7, 2004. Paris, France, 2004. 2004
Salloway S Pratt RD Perdomo CA The Donepezil 308 Study Group Donepezil treated patients with vascular dementia demonstrated cognitive and global benefits: results from Study 308, a 24-week randomized double-blind, placebo-controlled trial The 8th International Conference on Alzheiner's Disease and Related Disoreders, July 20-25, Stockholm, Sweden 2002 Abstract No 219
Salloway, 2002, Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients., European Journal of Neurology, 9, 165
Schindler R Perdomo CA Pratt RD Donepezil provides significant benefits to patients with vascular dementia in their ability to perform everyday activities. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004 2004
Seltzer, 2004, Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities, NeuroBiology of Aging, 25, 470, 10.1016/S0197-4580(04)81551-3
Wilkinson, 2003, Donepezil in vascular dementia a randomized placebo controlled study, Neurology, 61, 479, 10.1212/01.WNL.0000078943.50032.FC
Meyer, 2002, Donepezil treatment of vascular dementia, Annals of the New York Academy of Sciences, 977, 482, 10.1111/j.1749-6632.2002.tb04854.x
Rossor MN A 30 week open-label evaluation of a new agent in patients with dementia associated with cerebrovascular disease. National Research Register 2003
Shua-Haim, 2000, Donepezil (Aricept R) treatment of multi infarct dementia the caregivers and clinical impression, American Journal of Alzheimer's Disease, 15, 201, 10.1177/153331750001500408
American Psychiatric Association, 1944, Diagnostic and Statistical Manual of Mental Disorders
Berg, 1988, Clinical dementia rating (CDR), Psychopharmacology Bulletin, 24, 637
Bowen, 1976, Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies 6-Davis P, Malony AJF. 1976. Selective loss of central cholinergic neurons in alzheimer's disease. Lancet 1403, Brain, 99, 459, 10.1093/brain/99.3.459
Brust, 1988, Vascular dementia is overdiagnosed, Achives of Neurology, 45, 799, 10.1001/archneur.1988.00520310117026
Chui, 1992, Criteria for the diagnosis of ischaemic vascular dementia proposed by the state of California Alzheimer's Disease Diagnostic and Treatment centeres, Neurology, 42, 473, 10.1212/WNL.42.3.473
Crow, 1973, An analysis of the learning defict following hyoscine administration to man, British Journal of Pharmacology, 49, 322, 10.1111/j.1476-5381.1973.tb08379.x
Davis, 1976, Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, ii, 1403, 10.1016/S0140-6736(76)91936-X
Dawbarn, 2001, Neurobiology of Alzheimer's disease
Desmond, 1993, Risk factors for cerebrovascualr disease as correlates of cognitive function in a stroke free cohort, Archives of Neurology, 50, 162, 10.1001/archneur.1993.00540020040015
Ebly, 1995, Cognitive impairment in the non demented elderly result from the Canadian study of health and aging, Archiver of Neurology, 52, 612, 10.1001/archneur.1995.00540300086018
Folstein, 1975, Mini-mental state a practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6
Gearing, 1995, The Consortium to establish a registry for Alzheimer's disease (CERAD) Part X neuropathology confirmation of the clinical diagnosis of Alzheimer's disease, Neurology, 45, 461, 10.1212/WNL.45.3.461
Gottfries, 1994, The neurochemistry of vascular dementia, Dementia, 5, 163
Graham, 1997, Prevalence and severity of cognitive impairment with and without dementia in an elderly population, Lancet, 349, 1793, 10.1016/S0140-6736(97)01007-6
Hachinski, 1975, Cerebral blood flow in dementia, Archives of Neurology, 32, 632, 10.1001/archneur.1975.00490510088009
Hachinski, 1992, Preventable senility a call for action against the vascular dementias, Lancet, 340, 645, 10.1016/0140-6736(92)92177-H
Heyman, 1998, Cerebral infarction in patients with autopsy proven Alzheimer's disease CERAD part XVIII, Neurology, 51, 159, 10.1212/WNL.51.1.159
Hofman, 1991, The prevalence of dementia in Europe a collaborative study of 1980-1990 findings Eurodem prevalence research group, International of Journal of Epidemiology, 20, 736, 10.1093/ije/20.3.736
Jorm, 1991, Cross national comparisons of the occurrence of Alzheimer's disease and vascular dementias, European Archive of Psychaitry and Clinical neuroscience, 240, 218, 10.1007/BF02189530
Joynt, 1988, Vascular dementia too or too little, Archives of Neurology, 45, 801, 10.1001/archneur.1988.00520310119027
Knopman, 1994, The clinician interview based impression (CIBI) a clinician's global change rating scale in Alzheimer's disease, Journal of Neurology, 44, 2315, 10.1212/WNL.44.12.2315
Mann, The nucleus basalis of Meynert in multi infarct vascular dementia, Mann DMA, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi infarct vascular dementia, 71, 332
Meyer, 1995, Procpective CT confirms differences between vascular and Alzheimer's dementia, Stroke, 269, 735, 10.1161/01.STR.26.5.735
Meyer, 2002, Donepezil treatment of vascular dementia, Annals of the New York Academy of Sciences, 977, 482, 10.1111/j.1749-6632.2002.tb04854.x
Mohs, 2001, A 1 year placebo controlled preservation of function survival study of donepezil in AD patients, Neurology, 57, 481, 10.1212/WNL.57.3.481
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS), 2001, Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales, Lancet, 357, 169, 10.1016/S0140-6736(00)03589-3
Mulrow, 1997, Cochrane Collaboration Handbook
O'Brien, 1994, How does cerebrovascular disease cause dementia, De Mentia, 5, 133
O'Brien, 2001, Drugs for Alzheimer's disease, British Medical Journal, 323, 123, 10.1136/bmj.323.7305.123
O'Brien, 2003, Vascular cognitive impairment, The Lancet Neurology, 2, 89, 10.1016/S1474-4422(03)00305-3
Perry, 1977, Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activites in necropsy brain tissue, Journal of Neurological Science, 34, 247, 10.1016/0022-510X(77)90073-9
Rockwood, 1997, Presence and treatment of vascular risk factors in patients with vascular cognitive impairment, Archives of Neurology, 54, 33, 10.1001/archneur.1997.00550130019010
Rockwood, 2000, Prevalence and outcomes of vascular cognitive impairment, Neurology, 54, 447, 10.1212/WNL.54.2.447
Roman, 1993, Vascular dementia diagnostic criteria for research studies, Neurology, 43, 250, 10.1212/WNL.43.2.250
Rosen, 1984, A new rating scale for Alzheimer's disease, American Journal of Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356
Schwarz, 1999, Milameline (CI-979/RU35926) a muscarinic receptor agonist with cognition activating properties biochemical and in vivo characterization, Journal of Pharmacol Expermental Therapy, 291, 812
Snowdon, 1997, Brain infarction and the clinical expresion of Alzheimer's disease the nun study, Journal of the American Medical Association, 277, 813, 10.1001/jama.1997.03540340047031
Stewart, 1999, Type 2 diabetes mellitus cognitive impairment and dementia, Diabetes Med, 16, 93, 10.1046/j.1464-5491.1999.00027.x
Toghi, 1996, Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as copared with Alzheimer's type dementia, Journal of Neural Transmission, 103, 1211, 10.1007/BF01271206
Ueda, 1992, Prevalence and etiology of dementia in a Japanese community, Stroke, 23, 798, 10.1161/01.STR.23.6.798
World Health Organization, 1992, International Statistic Classification of Disease and Related Health Problems, 25
Zhang, 1990, The prevalence of dementia and Alzheimer's disease in Shanghai China impact of age gender and education, Annals of Neurology, 27, 428, 10.1002/ana.410270412
Zhang, 1998, Mechanism of nicotine induced relaxation in the porcine basilar artery, Journal of Pharmacology Expermental Therapy, 284, 790